Titan Biotech Limited

As of June 30, 2026, Titan Biotech Limited carries a market capitalization of 16.13B, placing it among publicly traded companies globally. Its enterprise value stands at 16.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Titan Biotech Limited has 51.65M shares outstanding.

As of June 30, 2026, Titan Biotech Limited trades at a trailing price-to-earnings ratio of 38.07.

As of June 30, 2026, Titan Biotech Limited trades at an EV/EBITDA multiple of 38.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 43.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 16.13B versus a market cap of 16.13B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.40M in revenue per employee across its workforce of 497.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Titan Biotech Limited recorded 120.54M in income tax expense. That works out to an effective tax rate of 28.17, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 427.97M, leaving 338.79M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Titan Biotech Limited's stock has gained approximately 71.15% over the past 52 weeks. The 50-day moving average sits at 321.75, while the 200-day moving average is 301.44.

Over the twelve months ended June 30, 2026, Titan Biotech Limited generated 2.19B in revenue and converted that into 338.79M in net income, yielding earnings per share of 8.04. EBITDA reached 423.54M, while operating income came in at 372.14M.

Over the twelve months ended June 30, 2026, Titan Biotech Limited posted a gross margin of 54.25, reflecting its pricing power and cost economics. The operating margin of 17.00 and net profit margin of 15.48 provide insight into operational efficiency.

Titan Biotech Limited's most recent stock split took place on October 23, 2026 with a 4:5 split ratio.